<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res</journal-id><journal-title-group><journal-title>Arthritis Research</journal-title></journal-title-group><issn pub-type="ppub">1465-9905</issn><issn pub-type="epub">1465-9913</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3273108</article-id><article-id pub-id-type="publisher-id">ar442</article-id><article-id pub-id-type="doi">10.1186/ar442</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Long term immune reconstitution after immunoablation and autologous CD34 cell therapy in autoimmune diseases</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Thiel</surname><given-names>AT</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Thiel</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Alexander</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Rosen</surname><given-names>O</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Gromnica-Ihle</surname><given-names>E</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Burmester</surname><given-names>GR</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Arnold</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Hiepe</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Radbruch</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>DRFZ Berlin, Berlin, Germany</aff><aff id="I2"><label>2</label>Haematology, Charit&#x000e9;, Berlin, Germany</aff><aff id="I3"><label>3</label>Rheumaklinik, Berlin-Buch, Berlin, Germany</aff><aff id="I4"><label>4</label>Rheumatology, Charit&#x000e9;, Berlin, Germany</aff><pub-date pub-type="ppub"><year>2002</year></pub-date><pub-date pub-type="epub"><day>4</day><month>2</month><year>2002</year></pub-date><volume>4</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">22nd European Workshop for Rheumatology Research</named-content><named-content content-type="supplement-sponsor">The organizer would like to thank the following companies who have generously supported the 22nd European Workshop for Rheumatology Research: Abbott/Knoll, MSD, Wyeth Ayerst, Amgen, Centocor, Novartis, Schering Plough, Aventis</named-content></supplement><fpage>107</fpage><lpage>107</lpage><history><date date-type="received"><day>15</day><month>1</month><year>2002</year></date></history><conference><conf-date>28 February - 3 March 2002</conf-date><conf-name>22nd European Workshop for Rheumatology Research</conf-name><conf-loc>Leiden, The Netherlands</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>Immunoablation in combination with autologous stem cell transplantation (ASCT) is used as a therapy for severe autoimmune diseases. We have analysed reconstitution of the immune system in patients treated with ASCT.</p></sec><sec><title>Results</title><p>During a follow-up period of up to 42 months after ASCT, one polychondritis and two systemic lupus erythematosus (SLE) patients in clinical remission were analysed for reappearance of naive, activated and memory B and T lymphocytes, for reactivity against pathogens and autoantigens, and for presence of autoantibodies. Titers of disease-specific autoantibodies decreased after ASCT with the half-life of secreted antibodies, and did not reappear. NaiveT and naive Bcells reappeared and reached normal levels within one year after ASCT. T cells activated and expanded by pathogens were easily detectable, but not T cells reacting to any of an array of autoantigens tested, in a cytometric cytokine provocation test. A third SLE patient suffered from a relapse of disease after being free of any clinical and serological symptoms for 17 months. In this patient, autoantibodies with old (anti-dsDNA antibodies) and new specificities (anti-Sm and anti-U1RNP antibodies) appeared upon relapse. A sudden decrease of peripheral naive and increase of peripheral memory B and Th cells preceeded the relapse.</p></sec><sec><title>Conclusion</title><p>ASCT for autoimmune diseases can result in longlasting remissions. According to frequencies and phenotypes of naive lymphocytes, the reconstituted immune system resembles a 'juvenile' immune system. Our results reveal that autoreactive and plasma cells do not survive the therapy but protective immune memory has to be re-established.</p></sec></body></article>